account... the new biosimilar deals are being driven by Big Pharma companies looking to garner significant revenue from this new generation of generics. Smaller players will find this a very tough game to play. Read more: Novartis biosimilars point to a blockbuster future - FierceBiotech http://www.fiercebiotech.com/story/novartis-biosimilars-point-blockbuster-future/2010-10-21#ixzz163OCfBxo
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to EU adopts new biosimilar guideline
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account